Automate Your Wheel Strategy on BCAB
With Tiblio's Option Bot, you can configure your own wheel strategy including BCAB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BCAB
- Rev/Share 0.188
- Book/Share -0.2862
- PB -1.4206
- Debt/Equity -0.361
- CurrentRatio 1.2417
- ROIC -5.2537
- MktCap 23876203.0
- FreeCF/Share -0.8943
- PFCF -0.4563
- PE -0.3997
- Debt/Assets 0.2228
- DivYield 0
- ROE -11.3173
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BCAB | Citizens JMP | Mkt Outperform | Market Perform | -- | -- | Aug. 13, 2025 |
News
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced an oral presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting to be held in Hong Kong Sar, China from July 18–20, 2025. Oral Presentation Details: Title: First-in-human phase I study of a dual-Conditionally Active Biologic (CAB) EpCAM x CD3 bispecific T-cell engager (TCE), BA3182, in patients with treatment refractory metastatic adenocarcinoma Authors: Jennifer B.
Read More
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy Marked unmet need exists in 2L+ HPV+ OPSCC patients; standard of care agents (methotrexate, docetaxel, or cetuximab) report an ORR of 3.4% Plan to finalize Phase 3 trial design in 2L+ HPV+ OPSCC with the U.S. Food and Drug Administration (FDA) SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment …
Read More
BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
BioAtla, Inc. (NASDAQ:BCAB ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Jeet Mukherjee – BTIG Reni Benjamin - Citizens JMP Arthur He - H.C. Wainwright Operator Good day, everyone, and welcome to today's BioAtla First Quarter 2025 Earnings Call.
Read More
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced two abstracts accepted for poster presentations at the upcoming European Lung Cancer Congress (ELCC) 2025 Scientific Committee and Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025, to be held in Paris, France from March 26–29, 2025 and in Scottsdale, AZ from March 27–29, 2025, respectively.
Read More
About BioAtla, Inc. (BCAB)
- IPO Date 2020-12-16
- Website https://www.bioatla.com
- Industry Biotechnology
- CEO Jay M. Short
- Employees 61